Guidolin V, Jacobs F, MacMillan M, Villalta P, Balbo S
Chem Res Toxicol. 2023; 36(8):1278-1289.
PMID: 37490747
PMC: 11231964.
DOI: 10.1021/acs.chemrestox.3c00008.
Otaegi-Ugartemendia M, Matheu A, Carrasco-Garcia E
Cancers (Basel). 2022; 14(6).
PMID: 35326607
PMC: 8946717.
DOI: 10.3390/cancers14061457.
Steinbrecht S, Kiebist J, Konig R, Thiessen M, Schmidtke K, Kammerer S
AMB Express. 2020; 10(1):128.
PMID: 32683510
PMC: 7368878.
DOI: 10.1186/s13568-020-01064-w.
Voronkova M, Rojanasakul L, Kiratipaiboon C, Rojanasakul Y
Mol Cell Biol. 2019; 40(2).
PMID: 31658996
PMC: 6944474.
DOI: 10.1128/MCB.00307-19.
Helsby N, Yong M, van Kan M, de Zoysa J, Burns K
Br J Clin Pharmacol. 2019; 85(9):1925-1934.
PMID: 31218720
PMC: 6710526.
DOI: 10.1111/bcp.14031.
Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer.
Goossens-Beumer I, Zeestraten E, Benard A, Christen T, Reimers M, Keijzer R
Br J Cancer. 2014; 110(12):2935-44.
PMID: 24786601
PMC: 4056050.
DOI: 10.1038/bjc.2014.226.
Development of selective inhibitors for aldehyde dehydrogenases based on substituted indole-2,3-diones.
Kimble-Hill A, Parajuli B, Chen C, Mochly-Rosen D, Hurley T
J Med Chem. 2014; 57(3):714-22.
PMID: 24444054
PMC: 3954746.
DOI: 10.1021/jm401377v.
Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.
Wang D, Wang H
Acta Pharm Sin B. 2013; 2(2).
PMID: 24349963
PMC: 3860377.
DOI: 10.1016/j.apsb.2012.02.004.
Cancer stem cells of differentiated B-cell malignancies: models and consequences.
Gross E, Quillet-Mary A, Ysebaert L, Laurent G, Fournie J
Cancers (Basel). 2013; 3(2):1566-79.
PMID: 24212774
PMC: 3757378.
DOI: 10.3390/cancers3021566.
The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.
Wang D, Li L, Yang H, Ferguson S, Baer M, Gartenhaus R
Blood. 2012; 121(2):329-38.
PMID: 23160467
PMC: 3544115.
DOI: 10.1182/blood-2012-06-436691.
Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.
Khanna M, Chen C, Kimble-Hill A, Parajuli B, Perez-Miller S, Baskaran S
J Biol Chem. 2011; 286(50):43486-94.
PMID: 22021038
PMC: 3234859.
DOI: 10.1074/jbc.M111.293597.
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
Awad O, Yustein J, Shah P, Gul N, Katuri V, ONeill A
PLoS One. 2010; 5(11):e13943.
PMID: 21085683
PMC: 2978678.
DOI: 10.1371/journal.pone.0013943.
A point mutation produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect of cyclophosphamide.
Ho K, Mukhopadhyay A, Li Y, Mukhopadhyay S, Weiner H
Biochem Pharmacol. 2008; 76(5):690-6.
PMID: 18647600
PMC: 2573387.
DOI: 10.1016/j.bcp.2008.06.018.
Clinical pharmacokinetics of cyclophosphamide.
de Jonge M, Huitema A, Rodenhuis S, Beijnen J
Clin Pharmacokinet. 2005; 44(11):1135-64.
PMID: 16231966
DOI: 10.2165/00003088-200544110-00003.